Swiss - Delayed Quote CHF

Novartis AG (NOVN.SW)

89.12

+0.18

(+0.20%)

At close: April 24 at 5:31 PM GMT+2

Advanced Chart

Loading Chart for NOVN.SW

9/21 12:03 PM

DELL

Previous Close 88.94
Open 90.00
Bid --
Ask --
Day's Range 89.07 - 90.33
52 Week Range 79.21 - 94.52
Volume 3,573,220
Avg. Volume 3,310,611
Market Cap (intraday) 181.841B
Beta (5Y Monthly) 0.47
PE Ratio (TTM) 23.83
EPS (TTM) 3.74
Earnings Date Jul 18, 2024
Forward Dividend & Yield 3.30 (3.71%)
Ex-Dividend Date Mar 7, 2024
1y Target Est 86.92

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

www.novartis.com

76,057

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - General

Industry

Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript

Company News for Apr 24, 2024

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Why Novartis Stock Topped the Market on Tuesday

FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Novartis Stock Jumps After Beating Expectations, Raising Guidance

Novartis Ag (NVS) Q1 2024 Earnings Call Transcript

Novartis raises full-year guidance on Q1 beat, drug sales

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Novartis raises full-year guidance on Q1 beat, drug sales

Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

MSCI WORLD

YTD Return

NOVN.SW

8.96%

MSCI WORLD

4.79%

1-Year Return

NOVN.SW

9.73%

MSCI WORLD

0.00%

3-Year Return

NOVN.SW

32.02%

MSCI WORLD

12.72%

5-Year Return

NOVN.SW

47.83%

MSCI WORLD

52.73%

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

NOVN.SW

Novartis AG

89.12

+0.20%

Mkt Cap CHF 181.841B